ASCO and ESMO Abstracts 2020

ASCO: Bintrafusp Alfa presented by Merck

Abstract No : 9558

Abstract Type : Poster Session

Indication : Non-Small Cell Lung Cancer

Intervention : Bintrafusp alfa (M7824)

Company : Merck KGaA, Darmstadt, Germany, Pharmaceutical/Biotech Company

Technology : Bifunctional fusion protein

After two years of follow-up, bintrafusp alfa continues to show manageable safety with durable responses and encouraging long-term survival, especially in patients with high PD-L1 expression. A study evaluating bintrafusp alfa vs pembrolizumab as first-line treatment for NSCLC is ongoing in patients with high PD-L1 expression (NCT03631706).

Read More: https://www.delveinsight.com/asco-conference/article/NCT02517398

ASCO: Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions

Abstract No : 9580

Abstract Type : Poster Session

Indication : NSCLC with EGFR exon 20 insertions

Intervention : TAK-788

Company : Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Technology : Small molecule

Despite a more heavily pretreated pt population, the efficacy of TAK-788 in pts with refractory NSCLC with EGFR exon 20 insertions appears better than other second-line treatment options used in the real-world setting.

Read More: https://www.delveinsight.com/asco-conference/article/NCT02716116

Adjuvant Therapy For High-risk Her2-positive Early Breast Cancer

Abstract No : 500

Indication : Her2 Positive Breast Cancer

Intervention : trastuzumab emtansine (T-DM1) + pertuzumab

Company : Roche

Technology : Monoclonal antibody

Replacing adjuvant taxane and trastuzumab with T-DM1 did not result in significantly improved efficacy or overall safety. Nonetheless, in this high-risk population, a favorable IDFS outcome was achieved in both study arms. HP + chemotherapy remains the standard of care for patients with high-risk HER2-positive EBC.

Read More: https://www.delveinsight.com/asco-conference/article/trastuzumab-emtansine-pertuzumab

ESMO: Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease-associated ccRCC

Abstract No : Abstract #LBA26

Indication : Renal cell carcinoma

Intervention : MK 6482 + cabozantinib

Company : Merck & Co.

Technology : PD-1/MultiTKI Inhibitor

MK6482 continued to demonstrate promising antitumor activity against VHL-associated RCC and non-RCC tumors and was well tolerated

Read More: https://www.delveinsight.com/esmo-conference-2020/article/NCT03401788-esmo-2020